We propose that pioglitazone, a Peroxisome Proliferator Activated Receptor Gamma (PPARγ) agonist, may reduce the incidence of death or BPD and may improve neurodevelopment in extreme preterm babies. This evidence concerns the gene PPARG and bronchopulmonary dysplasia.